Estrategias actuales para el manejo multidisciplinario del cáncer de páncreas en estadios resecables y localmente avanzados
Palabras clave:
Neoplasias pancreáticas, comunicación interdisciplinaria, cambio de tratamiento.Resumen
Introducción: El cáncer de páncreas constituye una de las neoplasias más letales del tracto digestivo, con una baja tasa de supervivencia a los cinco años. Su complejidad clínica y biológica exige un abordaje terapéutico integral. En los estadios resecables y localmente avanzados, solo el manejo multidisciplinario puede mejorar los resultados clínicos.
Objetivo: Revisar y actualizar de forma crítica, las estrategias actuales para el manejo multidisciplinario del cáncer de páncreas en estadios resecables y localmente avanzados.
Métodos: Se realizó una revisión sistemática de la literatura científica en PubMed, Scopus, Web of Science, Embase y SciElo, desde enero de 2019 a junio de 2025. Fueron aplicados criterios de inclusión y exclusión, a fin de alcanzar los objetivos planteados. Se incluyeron 40 referencias relevantes, con el cumplimiento de las directrices EQUATOR.
Resultados: Se describen los criterios actuales de clasificación por estadio y resecabilidad, el papel de los comités multidisciplinarios, la selección de pacientes para resección quirúrgica, la utilización de neoadyuvancia, el impacto de las técnicas quirúrgicas modernas, las terapias adyuvantes, el seguimiento postoperatorio y el rol emergente de la medicina personalizada.
Conclusiones: El enfoque multidisciplinario representa el pilar esencial para optimizar el tratamiento del cáncer pancreático resecable y localmente avanzado. La integración coordinada de especialidades permite una selección más precisa de pacientes candidatos a la intervención quirúrgica, reduce complicaciones y mejora la supervivencia. La actualización constante de las estrategias diagnósticas y terapéuticas resultan clave para enfrentar los desafíos clínicos de esta enfermedad.
Descargas
Citas
1. Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. American Cancer Society Journals [Internet]. 2021;71(3):209-49. [access: 01/05/2025]. Available from: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21660
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. American Cancer Society Journals [Internet]. 2022 72(1):7-33. [access: 16/06/2025]. Available from: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21708
3. Puckett Y, Garfield K. Pancreatic cancer [Internet]. United States of America: National Library of Medicine; 2024. [access: 16/06/2025]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK518996/
4. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. The Lancet [Internet]. 2020;395(10242):2008-20. [access: 16/06/2025]. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30974-0/fulltext
5. Schepis T, De Lucia SS, Pellegrino A, Gaudio A, Maresca R, Coppola G, et al. State-of-the-Art and Upcoming Innovations in Pancreatic Cancer Care: A Step Forward to Precision Medicine. Cancers [Internet]. 2023;15(13):3423. [access: 16/06/2025]Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10341055/
6. Sohal DP, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, et al. Metastatic pancreatic cancer: ASCO guideline update. Journal of Clinical Oncology [Internet]. 2020;38(27):3217-31. [access: 16/06/2025]. Available from: https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.01364
7. Versteijne E, Suker M, Groothuis K, Janine MA, Marc GB, Bert AB, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Journal of Clinical Oncology [Internet];38(16):1-12. 2020 [access: 20/06/2025]. Available from: https://ascopubs.org/doi/pdf/10.1200/JCO.19.02274
8. Cecchini M, Salem RR, Robert M. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer A Nonrandomized Clinical Trial. JAMA Oncology [Internet]. 2024;10(8):1027-35. [access: 20/06/2025]. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2820217
9. Drake J, Anaya, DA, Fleming JB, Denbo JW. Surgery for Borderline Resectable Pancreatic Ductal Adenocarcinoma Preoperative Planning, Technical Considerations, and Building a Program. Surgical Clinics [Internet]. 2024 [access: 20/06/2025];104(5)1031-48. Available from: https://www.surgical.theclinics.com/article/S0039-6109(24)00100-2/abstract
10. Cortina V, Vallabhaneni H, Gambill J, Nadar S, Itodo K, Park Ch, et al. Advancing Pancreatic Cancer Surgical Treatments and Proposal of New Approaches. Cancers [Internet]. 2024;16(16):2848-60. [access: 20/06/2025]. Available from: https://www.mdpi.com/2072-6694/16/16/2848
11. Takahashi S. Perioperative treatments for borderline resectable pancreatic cancer. Annals of Oncology [Internet]. 2021;32(4):265. [access: 20/06/2025]. Available from: https://www.annalsofoncology.org/article/S0923-7534(21)01669-0/fulltext
12. Abreu LF, Gryspeerdt F, Rashidian N, Hove K. Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities? BMC Surgery [Internet]. 2023;23(1):296-308. [access: 04/07/2025]. Available from: https://www.researchgate.net/publication/374328833_Predictive_factors_for_survival_in_borderline_resectable_and_locally_advanced_pancreatic_cancer_are_these_really_two_different_entities
13. Rangelova E, Stoop TF, Ramshorst TM. Del Chiaro, M. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Annals of Oncology [Internet]. 2025;36(5):529-42. [access: 04/07/2025]. Available from: https://www.annalsofoncology.org/article/S0923-7534(25)00004-3/fulltext
14. Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe Ch. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. The Lancet [Internet] 2023;8(2):157-68. [access: 04/07/2025]. Available from: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(22)00348-X/fulltext
15. Conroy T, Castan F, Lopez A, Turpin A, Abdelghani M, Wei AC, et al. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer A Randomized Clinical Trial. JAMA Oncology [Internet]. 2022;8(11):1571-8. [access: 04/07/2025]. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2795978
16. Tanially E, Cendera C, Cheryl A, Tejayadi J, Wijaya D, Pramana A. Efficacy and safety of FOLFIRINOX in comparison to gemcitabine as adjuvant therapy for PC patients: a systematic review. Annals of Oncology [Internet]. 2024;35(3):1329. [access: 04/07/2025]. Available from: https://www.annalsofoncology.org/article/S0923-7534(24)01290-0/fulltext
17. Botta GP, Huynh TR, Spierling-Bagsic SR, Agelidis A, Schaffer R, Lin Ray, et al. Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients. Cancer Medicine [Internet]. 2022;12(7):7713-23. [access: 17/07/2025]. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.5523
18. Klein Brill A, Amar Farkash S, Lawrence G. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JAMA Network [Internet]. 2022;5(6):16199. [access: 17/07/2025]. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793152
19. Chun JW, Lee SH, Kim JS, Park N, Huh N, Cho IR, et al. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach. BMC Cancer [Internet]. 2021 21(537):1-11. [access: 17/07/2025]. Available from: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08277-7
20. Zureikat AH, Beane JD, Zenati MS, Abbas AI, Boone BA, Moser AJ, et al. 500 Minimally Invasive Robotic Pancreatoduodenectomies. National Library of Medicine [Internet]. 2021];273(5):966-72. [access: 17/07/2025Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7871451/
21. Tang YCh, Liu QQ, He YG, Li J, Huang XB. Laparoscopic pancreaticoduodenectomy: a retrospective study of 200 cases and the optimization of the single-center learning curve. Translational Cancer Research [Internet]. 2021;10(7):3436-47. [access: 17/07/2025]. Available from: https://tcr.amegroups.org/article/view/53023/html
22. Tuveson D, Allen P. The evolving role for surgery in pancreatic cancer. Carcinogenesis [Internet]. 2024;45(11):823-5. [access: 17/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/39514563/
23. Vaalavuo Y, Siiki A, Antila A, Rinta-Kiikka I, Sanda J, Laukkarinen J. The European evidence-based guidelines on pancreatic cystic neoplasms (PCN) in clinical practice: The development of relative and absolute indications for surgery during prospective IPMN surveillance. Pancreatology [Internet]. 2020;20(7):1393-8. [access: 17/07/2025]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1424390320307031
24. Neilson T, Cloyd JM. Neoadjuvant mFOLFIRINOX for resectable pancreatic cancer: increasing evidence, ongoing challenges. Translational Gastroenterology and Hepatology [Internet]. 2025;10(22):1027. [access: 22/07/2025]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12056118/
25. Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Therapeutic Advances in Gastroenterology [Internet]. 2019;12(19):1-9. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/31598136/
26. Okano N, Sakamaki K, Mie T, Watanabe K, Kobayashi S, Todaka A. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity score-matched análisis [Internet]. Japan: Elsevier; 2025. [access: 22/07/2025]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1424390325005915?dgcid=rss_sd_all
27. Ben Q, Sun Y, Liu J, Wang W, Zou D, Yuan Y. Nicotine promotes tumor progression and epithelial-mesenchymal transition by regulating the miR-155-5p/NDFIP1 axis in pancreatic ductal adenocarcinoma. Pancreatology [Internet]. 2020;20(4):698-708. [access: 22/07/2025]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1424390320301332
28. Nevala Plagemann C, Hidalgo M, Garrido Laguna I. From state-of-the-art treatment to novel therapies for advanced-stage pancreatic cancer. National Library of Medicine [Internet]. 2020;17(2):108-23. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/31705130/
29. Rosado JE, Sohn ASW, Biancur DE, Lin EY, Osorio V, Rodrick T, et al. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. National Library of Medicine [Internet]. 2024;5(1):85-99. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/37814010/
30. Goess R, Jäger C, Perinel J, Pergolini I, Demir E, Safak O, et al. Lymph node examination and survival in resected pancreatic ductal adenocarcinoma: retrospective study. BJS Open [Internet]. 2024;8(1):234. [access: 22/07/2025]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10810280/
31. Formelli MG, Palloni A, Tavolari S, Deiana, Ch, Andrini E, Di Marco M, et al. Classic versus innovative strategies for immuno-therapy in pancreatic cancer. Advanced Drug Delivery Reviews [Internet]. 2025;225(25):1-20. [access: 22/07/2025]. Available from: https://www.sciencedirect.com/science/article/pii/S0169409X25001565
32. Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: Challenges and opportunities. Gastroenterology [Internet]. 2019;156(7):2056-72. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/30660727/
33. Prattico F, Garajová I. Focus on Pancreatic Cancer Microenvironment. Curr Oncol [Internet]. 2024;31(8):4241-60. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/39195299/
34. Bear AS, Vonderheide RH, O'Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell [Internet]. 2020;38(6):788-802. [acceso: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/32946773/
35. Li Y, Tang J, Jiang J, Chen Z. Metabolic checkpoints and novel approaches for immunotherapy against cancer. Int J Cancer [Internet]. 2021;150(2):195-207. [access: 22/07/2025]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9298207/
36. Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: An update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol [Internet]. 2020;17(8):487-505. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/32393771/
37. Sherpally D, Manne A. Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies. Cancer Immunotherapy in Clinical and Translational Research [Internet]. 2025;17(4):589. [access: 22/07/2025]. Available from: https://www.mdpi.com/2072-6694/17/4/589
38. Delitto D, Wallet SM, Hughes SJ. Targeting the pancreatic cancer immune microenvironment. Surg Oncol Clin N Am [Internet]. 2019;19(6):473-82. [acceso: 22/07/2025]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6548630/
39. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov [Internet]. 2019;18(3):197-218. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/30610226/
40. Di Marco M, Frassineti GL, Clavien PA. Critical analysis of current guidelines for the management of pancreatic cancer. Pancreatology [Internet]. 2021;21(8):1571-82. [access: 22/07/2025]. Available from: https://www.pancreatologyjournal.org/article/S1424-3903(21)00229-7/fulltext
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Roberto Lázaro Blanco Sosa, Olivia El Achtar, Milton Manuel Sánchez García , Carlos David Garcia Martin
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia Creative Commons Atribución– No Comercial 4.0 que permite el uso, distribución y reproducción no comerciales y sin restricciones en cualquier medio, siempre que sea debidamente citada la fuente primaria de publicación.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada.
Instrucciones a autores(as) - Descargar 
